Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PSNLBullishM&Anews

High materiality8/10

Tempus AI to acquire Personalis for about $1.5B, expanding oncology portfolio

Jul 20, 2026, 8:56 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Acquisition by a well-funded strategic buyer typically leads to immediate premium and valuation rerating for PSNL, though closing and integration risks exist.

AI summary

What happened, with direct paths to the underlying reporting

Tempus AI agreed to acquire Personalis for about $1.5 billion, integrating PSNL into its oncology-focused, AI-enabled precision medicine strategy. The deal signals a strategic premium for PSNL and could catalyze near-term re-rating as Tempus expands its cancer-testing capabilities. Regulatory approvals and financing structure will determine closing timing and eventual impact on PSNL's valuation.

Tempus AI to acquire Personalis for about $1.5B, expanding oncology portfolio.
Deal integrates PSNL's cancer test into Tempus's AI-enabled precision medicine platform.
No terms on financing or closing timing; impact on PSNL shareholders pending.
Public announcement made on Monday; regulatory and integration risks remain.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tempus AI to acquire Personalis for about $1.5B, expanding oncology portfolio

Medicare Expands Coverage for Personalis' NeXT Personal Breast Cancer Test

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session